EU Approves Hospira's Inflectra In Biosimilars Milestone

Law360, New York (September 10, 2013, 7:03 PM EDT) -- Hospira Inc. on Tuesday said the European Commission has approved Inflectra, its copycat version of Johnson & Johnson’s blockbuster biologic drug Remicade, marking a historic day for development of highly advanced biosimilars.

Clearance was expected after European Medicines Agency officials earlier this year gave their blessing to Hospira's version of infliximab, a so-called monoclonal antibody drug that is more complex than any of the biosimilars previously approved in Europe.

Dr. Stan Bukofzer, chief medical officer at Hospira, called the authorization a "major milestone for Inflectra and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.